• RG7388: Selective p53-MDM2 Inhibitor for Translational On...

  2026-02-26

  RG7388 empowers researchers with unmatched potency and selectivity as an MDM2 antagonist, enabling precise p53 pathway activation and robust cancer cell apoptosis induction. Its integration into combination therapy workflows accelerates breakthroughs in solid and hematological tumor models, while optimized protocols and troubleshooting strategies maximize experimental reliability.

• Fulvestrant (ICI 182,780): Advanced Estrogen Receptor Ant...

  2026-02-26

  Fulvestrant (ICI 182,780) delivers precision modulation of estrogen receptor signaling, setting new standards in ER-positive breast cancer research and immune-endocrine studies. This guide explores optimized protocols, troubleshooting strategies, and innovative use-cases, positioning APExBIO's Fulvestrant as an indispensable tool for translational and preclinical investigations.

• Abiraterone Acetate: Atomic Facts on CYP17 Inhibition in ...

  2026-02-25

  Abiraterone acetate, a potent CYP17 inhibitor and 3β-acetate prodrug of abiraterone, is fundamental in castration-resistant prostate cancer treatment and research. This article provides atomic, machine-readable facts on its mechanism, benchmarks, and experimental integration. APExBIO's high-purity Abiraterone acetate (SKU A8202) enables precise interrogation of androgen biosynthesis and steroidogenesis pathways.

• Fulvestrant (ICI 182,780): High-Affinity Estrogen Recepto...

  2026-02-25

  Fulvestrant (ICI 182,780) is a potent estrogen receptor antagonist widely used in ER-positive breast cancer studies. Its mechanism involves high-affinity ER binding, receptor degradation, and MDM2 protein downregulation, which together sensitize cancer cells to chemotherapy and enable modeling of endocrine therapy resistance.

• Fulvestrant (ICI 182,780): Benchmark Estrogen Receptor An...

  2026-02-24

  Fulvestrant (ICI 182,780) is a potent, specific estrogen receptor antagonist widely used in ER-positive breast cancer research. This article details its mechanism as an ER degrader, benchmarks its efficacy in chemotherapeutic sensitization, and clarifies practical limits for workflow integration. APExBIO's Fulvestrant supports reproducible, high-fidelity studies of endocrine therapy resistance.

• Strategic Horizons in Translational Oncology: Mechanistic...

  2026-02-24

  This thought-leadership article provides translational researchers with a strategic, mechanistic deep dive into the deployment of RG7388—a next-generation, highly selective MDM2 antagonist—for optimized p53 pathway activation, apoptosis induction, and enhanced chemoradiotherapy response in cancer models. By integrating the latest biomarker-driven insights, preclinical data, and clinical foresight, we define new paradigms for combination therapies and precision oncology, moving beyond conventional product literature to offer actionable, evidence-based guidance.

• Fulvestrant (ICI 182,780): Advanced Insights into ER Anta...

  2026-02-23

  Explore how Fulvestrant (ICI 182,780), a potent estrogen receptor antagonist, not only advances ER-positive breast cancer treatment but also reveals novel immunological and cell stress pathways. Delve into mechanistic and translational breakthroughs that set this article apart.

• RITA (NSC 652287): Precision MDM2-p53 Inhibitor for Cance...

  2026-02-23

  RITA (NSC 652287) from APExBIO uniquely combines nanomolar potency, selectivity, and reproducible performance as a p53 activator for cancer research. This guide details how to leverage RITA in advanced experimental designs—spanning apoptosis assays to tumor xenograft models—and provides actionable troubleshooting strategies for maximizing data quality.

• Mechanistic Disruption and Translational Opportunity: Tor...

  2026-02-22

  This thought-leadership article explores the intersecting roles of estrogen receptor modulation and calcium signaling in prostate cancer metastasis, with a focus on the translational utility of Toremifene—a second-generation selective estrogen-receptor modulator (SERM) from APExBIO. Drawing on new mechanistic insights into the TSPAN18-STIM1 axis, we chart experimental strategies, highlight competitive considerations, and articulate a forward-looking vision for hormone-responsive cancer research.

• RG7388: Selective MDM2 Antagonist for p53 Pathway Activat...

  2026-02-21

  RG7388 is a highly potent, selective MDM2 antagonist that activates the p53 tumor suppressor pathway in wild-type p53 cancer cells. This compound induces cell cycle arrest and apoptosis, offering robust efficacy in preclinical cancer models and unique synergy with chemotherapy and radiation. Its specificity and superior potency position it as a leading candidate for translational oncology applications targeting solid and hematological tumors.

• Fulvestrant (ICI 182,780): Unraveling ER Antagonism and I...

  2026-02-20

  Explore how Fulvestrant (ICI 182,780), a potent estrogen receptor antagonist, drives breakthrough research in ER-positive breast cancer by linking receptor signaling, immune modulation, and chemotherapy sensitization. This article offers an advanced analysis of molecular mechanisms and experimental strategies, setting it apart from conventional reviews.

• Solving Lab Challenges with Fulvestrant (ICI 182,780): Pr...

  2026-02-20

  This article provides a scenario-driven, evidence-based exploration of Fulvestrant (ICI 182,780) (SKU A1428) for researchers studying ER-positive breast cancer. Drawing on peer-reviewed literature and benchmarked workflows, we address real laboratory challenges—from assay reproducibility to vendor selection—while highlighting how SKU A1428 supports sensitive, robust, and cost-efficient experimental outcomes.

• MDV3100 (Enzalutamide): Nonsteroidal Androgen Receptor An...

  2026-02-19

  MDV3100, also known as Enzalutamide, is a potent nonsteroidal androgen receptor antagonist designed for prostate cancer research. Its unique mechanism blocks androgen receptor signaling, induces apoptosis in AR-amplified prostate cancer cell lines, and serves as a benchmark tool for investigating castration-resistant prostate cancer pathways.

• Abiraterone Acetate: Optimizing CYP17 Inhibition in Prost...

  2026-02-19

  Unlock the full translational power of Abiraterone acetate—a potent CYP17 inhibitor and 3β-acetate prodrug of abiraterone—for advanced prostate cancer research. This guide delivers stepwise protocols, 3D spheroid workflow enhancements, and troubleshooting strategies to maximize reproducibility and androgen receptor inhibition in your in vitro and in vivo assays.

• Fulvestrant (ICI 182,780): Potent Estrogen Receptor Antag...

  2026-02-18

  Fulvestrant (ICI 182,780) is a high-affinity estrogen receptor antagonist and a validated tool for studying ER-positive breast cancer treatment and endocrine therapy resistance. Its use enables precise downregulation of ER-mediated signaling, MDM2 degradation, and apoptosis induction in cancer models. APExBIO supplies Fulvestrant in research-grade quality to ensure reproducible, high-impact results.

241 records 6/17 page Previous Next First page 上5页 678910 下5页 Last page